OverviewDosage GuideSide EffectsProtocolResultsWeight LossClinical TrialsInjection GuideGLP-3How to GetCostFDA ApprovalAvailabilityTelehealthLiver FatMuscle LossWhere to Buy
Retatrutide Protocol Guide
A structured protocol for using Retatrutide: cycle length, administration timing, stacking considerations, and monitoring.
Protocol Overview
Recommended Cycle Length
12–52 weeks (chronic use)
Dosing Frequency
Once weekly
Administration Route
Subcutaneous injection (abdomen, thigh, upper arm)
Titration Required
Yes — see schedule
Week-by-Week Titration Protocol
1
Week
2mg
Starting dose — monitor for side effects
4
Week
4mg
Increase if previous dose was well-tolerated
8
Week
8mg
Increase if previous dose was well-tolerated
12
Week
12mg
Increase if previous dose was well-tolerated
16
Week
16mg
Increase if previous dose was well-tolerated
20
Week
20mg
Increase if previous dose was well-tolerated
24
Week
24mg
Maximum / maintenance dose
Stacking & Combination Protocols
Important: Stacking Retatrutide with other active compounds significantly increases the complexity of managing side effects and monitoring. Always consult a qualified healthcare provider before combining compounds.
Commonly Discussed Combinations
Cagrilintide
Research only — no approved combination existsAmylin analogue — Cagrisema (cagrilintide + semaglutide) trials show additive satiety effects. In theory, combining with Retatrutide could further enhance weight loss through complementary mechanisms.
Synergy: High potential
MOTS-c
Research onlyMitochondrial-derived peptide that may enhance metabolic efficiency and fat oxidation. Believed to complement GLP-1 class drugs by addressing insulin resistance at the cellular level.
Synergy: Theoretical
CJC-1295 / Ipamorelin
Anecdotal onlyGrowth hormone secretagogues. Sometimes used alongside weight-loss peptides for lean mass preservation during aggressive caloric restriction. No clinical data on combination with Retatrutide.
Synergy: Low / off-protocol
Do NOT Stack With
✗
Other GLP-1 agonists (semaglutide, tirzepatide)
Redundant mechanism, significantly elevated GI side effect risk, no clinical rationale
✗
Other GLP-1/GIP dual or triple agonists
Same receptor targets — additive side effects without additive benefit
✗
Insulin (without medical supervision)
Hypoglycemia risk — if diabetic and on insulin, dose reduction is required under medical guidance
Related Peptides
tirzepatide— commonly compared / discussed alongside Retatrutide
Learn more →semaglutide— commonly compared / discussed alongside Retatrutide
Learn more →ipamorelin— commonly compared / discussed alongside Retatrutide
Learn more →Monitoring While on Protocol
- ✓Track body weight weekly
- ✓Monitor blood glucose if diabetic or pre-diabetic
- ✓Check lipid panel and liver enzymes at baseline and every 3 months
- ✓Document side effects and dose response in a log
- ✓Schedule follow-up with prescribing provider every 4–8 weeks initially
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.
Medical Disclaimer: This protocol guide is for informational purposes only and is based on available research. It does not constitute medical advice. Work with a licensed healthcare provider to design and monitor your peptide protocol.